Information Hub

Clinical News

2019-03-05

Trastuzumab, capecitabine, oxaliplatin and pembrolizumab as first-line treatment demonstrates encouraging activity in HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma

Combination of trastuzumab, capecitabine, oxaliplatin and pembrolizumab showed promising results in patients with HER2-positive metastatic esophagogastric cancer.

Source:

J Clin Oncol

2018-12-04

Olaparib significantly improves PFS in BRCA-mutated ovarian cancer as frontline maintenance therapy

In the phase 3 SOLO-1 study, olaparib as frontline maintenance therapy showed significant PFS improvement in ovarian cancer patients carrying BRCA mutation

Source:

N Engl J Med

2018-12-04

Rucaparib shows encouraging anti-tumor activity in metastatic castration-resistant prostate cancer with a deleterious BRCA alteration

According to the preliminary data of TRITON2 study, rucaparib showed anti-tumor activity in metastatic castration-resistant prostate cancer patients carrying BRCA mutation.

Source:

Annals of Oncology

2018-12-04

FDA granted accelerated approval of lorlatinib in ALK+ NSCLC

Based on data from a phase II study (B7461001), the FDA approved lorlatinib for the treatment of patients with ALK positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors (TKIs)

Source:

FDA

2018-12-04

Infigratinib shows meaningful clinical activity in patients with intrahepatic cholangiocarcinoma (IHC) containing FGFR2 fusions

According to updated phase II findings presented at the 2018 ESMO Congress, infigratinib, a selective pan-FGFR kinase inhibitor, demonstrated a clinical meaningful activity in patients with IHC.

Source:

2018 ESMO Congress

2018-12-04

A combination therapy can be used to control the disease of osimertinib-resistant lung cancer patients with RET gene fusion

This study indicated that RET fusion mutation is one of the mechanisms of drug resistance in EGFR-mutant lung cancer patients after osimertinib treatment. A combination therapy provides a new strategy to overcome the drug resistance

Source:

Piotrowska Z, et al., Cancer Discov

2018-11-01

FDA Approves Anti-PD-1 Antibody Cemiplimab for CSCC

The U.S. FDA approves PD-1 inhibitor cemiplimab-rwlc (Libtayo) for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC).

Source:

N Engl J Med. &J Clin Oncol.

2018-11-01

Repotrectinib Shows Significant Clinical Activity in ROS1+ NSCLC

In the phase I/II TRIDENT-1 study, repotrectinib demonstrates a clinically meaningful response in non-small cell lung cancer (NSCLC) patients carrying ROS1 fusion.

Source:

The IASLC 19th World Conference on Lung Cancer

2018-11-01

Brigatinib Shows Promising Results as First Line for ALK+ Lung Cancer

In the phase 3 ALTA-1L study, brigatinib significantly prolongs the progression-free survival (PFS) compared to crizotinib in adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC).

Source:

N Engl J Med.

2018-11-01

PARP/Immunotherapy Combo Offers New Opportunities in Ovarian Cancer

There are limited treatment options in platinum-resistance/refractory ovarian cancer patients. The phase I/II TOPACIO/KEYNOTE-162 study shows that the combination of PARP inhibitor and a PD-1 inhibitor can achieve response in difficult-to treat patients.

Source:

J Clin Oncol.

日韩av电影,色YEYE高清在线视频,欧美XXZOZO,JAPANESE 18日本护士